Literature DB >> 11854286

Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP).

Minna Kärkkäinen1, Tomoichiro Oka, Vesa M Olkkonen, Jari Metso, Hiroaki Hattori, Matti Jauhiainen, Christian Ehnholm.   

Abstract

Plasma phospholipid transfer protein (PLTP) plays an important role in lipoprotein metabolism. Two forms of PLTP exist in human plasma, one catalytically active (high activity form, HA-PLTP) and the other inactive (low activity form, LA-PLTP) (Oka, T., Kujiraoka, T., Ito, M., Egashira, T., Takahashi, S., Nanjee, N. M., Miller, N. E., Metso, J., Olkkonen, V. M., Ehnholm, C., Jauhiainen, M., and Hattori, H. (2000) J. Lipid Res. 41, 1651-1657). The two forms are associated with macromolecular complexes of different size. The apparent size of LA-PLTP is 520 kDa and that of HA-PLTP is 160 kDa. Of the circulating PLTP mass only a minor portion is in the HA-PLTP form in normolipidemic subjects. In the present study we have isolated and partially characterized the LA and HA forms of PLTP. Both LA- and HA-PLTP bind to heparin-Sepharose and can be separated by elution with 0-0.5 m NaCl gradient, with HA-PLTP displaying higher affinity for the matrix. LA-PLTP was further purified using hydrophobic butyl-Sepharose and anti-PLTP immunoaffinity chromatography steps. HA-PLTP was subjected to a second heparin-Sepharose step and hydroxylapatite chromatography. Analysis of the two forms of PLTP by SDS-PAGE, Western blotting, immunoprecipitation, and gel filtration demonstrates that LA-PLTP is complexed with apoA-I whereas HA-PLTP is not. Instead, HA-PLTP copurified with apoE. Based on these findings we suggest a model in which nascent PLTP enters the circulation as a high specific activity form not associated with apoA-I. During or after the transfer of lipolytic surface remnants to HDL, PLTP is transferred to apoA-I-containing HDL particles and thereby becomes part of the low activity complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854286     DOI: 10.1074/jbc.M112247200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition.

Authors:  Richard E Morton; Diane J Greene
Journal:  J Lipid Res       Date:  2011-09-21       Impact factor: 5.922

2.  Dry eye symptoms are increased in mice deficient in phospholipid transfer protein (PLTP).

Authors:  Niko L Setälä; Jari Metso; Matti Jauhiainen; Antti Sajantila; Juha M Holopainen
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 3.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Interaction of phospholipid transfer protein with human tear fluid mucins.

Authors:  Niko L Setälä; Juha M Holopainen; Jari Metso; Gebrenegus Yohannes; Jaakko Hiidenhovi; Leif C Andersson; Ove Eriksson; Alexandra Robciuc; Matti Jauhiainen
Journal:  J Lipid Res       Date:  2010-08-19       Impact factor: 5.922

Review 5.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

6.  Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity.

Authors:  Marian C Cheung; Gertrud Wolfbauer; John J Albers
Journal:  Biochim Biophys Acta       Date:  2011-02-16

7.  Human apoA-I increases macrophage foam cell derived PLTP activity without affecting the PLTP mass.

Authors:  Marius R Robciuc; Jari Metso; Anca Sima; Christian Ehnholm; Matti Jauhiainen
Journal:  Lipids Health Dis       Date:  2010-06-09       Impact factor: 3.876

8.  Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology.

Authors:  Marian C Cheung; Gertrud Wolfbauer; Hiroshi Deguchi; José A Fernández; John H Griffin; John J Albers
Journal:  Biochim Biophys Acta       Date:  2008-12-30

9.  PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study.

Authors:  Axel Schlitt; Stefan Blankenberg; Christoph Bickel; Karl J Lackner; Gunnar H Heine; Michael Buerke; Karl Werdan; Lars Maegdefessel; Uwe Raaz; Hans J Rupprecht; Thomas Munzel; Xian-Cheng Jiang
Journal:  J Lipid Res       Date:  2008-11-10       Impact factor: 5.922

10.  Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma.

Authors:  Ryan J Henderson; Kishor M Wasan; Carlos G Leon
Journal:  Lipids Health Dis       Date:  2009-07-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.